Author

K. Kishida

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Arakawa· 2 shared A. Nakagawa· 2 shared A. Tada· 2 shared C. Ono· 2 shared D. M. Standley· 2 shared H. Arase· 2 shared H. Jin· 2 shared H. Nakagami· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Arakawa

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chimeric systems composed of swapped Tra subunits between distantly-related F plasmids reveal striking plasticity among type IV secretion machines

P. Christie, K. Kishida, Y. G. Li, N. Ogawa-Kishida, P. Khara, A. A. M. Al Mamun, R. E. Bosserman

This study constructs chimeric T4SSs by swapping subunits between distantly-related F plasmids, revealing structural and functional flexibility in type IV secretion systems.

bioRxiv · Dec 5, 2023Microbiology

Ligand-Displaying E. coli Cells and Minicells for Programmable Delivery of Toxic Payloads via Type IV Secretion Systems

P. J. Christie, Y. G. Li, K. Kishida, N. Ogawa-Kishida

This study demonstrates the use of ligand-displaying E. coli cells and minicells to deliver toxic payloads via T4SSs, enhancing conjugative transfer and killing specific bacterial targets.

bioRxiv · Aug 11, 2023 · PreprintMicrobiology

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

Y. Liu, N. Arase, J.-i. Kishikawa, M. Hirose, S. Li, A. Tada, S. Matsuoka, A. Arakawa, K. Akamatsu, C. Ono, H. Jin, K. Kishida, W. Nakai, M. Kohyama, A. Nakagawa, , H. Arase

The paper shows the Delta variant can escape NTD antibodies and gain infectivity when specific RBD mutations are present, suggesting the need for updated vaccines.

bioRxiv · Aug 22, 2021 · PreprintMicrobiology

An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies

Y. Liu, W. T. Soh, A. Tada, A. Arakawa, S. Matsuoka, E. E. Nakayama, S. Li, C. Ono, S. Torii, K. Kishida, H. Jin, W. Nakai, N. Arase, A. Nakagawa, Y. Shindo, , H. Arase

This study identifies an NTD site on SARS-CoV-2 spike protein that enhances infectivity when targeted by antibodies, and finds these antibodies are present in hospitalized patients and some uninfected donors.

bioRxiv · Dec 18, 2020Microbiology